Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease
- PMID: 11752030
- DOI: 10.1681/ASN.V131134
Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease
Abstract
Adiponectin (ADPN), which is a secretory protein of adipose tissue, attenuates endothelial inflammatory responses in vitro. Among human subjects, plasma ADPN concentrations are reduced among patients with atherosclerotic complications but are substantially increased among patients with advanced renal failure. The clinical and biochemical correlates of plasma ADPN levels were investigated and the predictive power of ADPN levels with respect to survival rates and cardiovascular events was prospectively tested in a cohort of 227 hemodialysis patients, who were monitored for 31 +/- 13 mo. Plasma ADPN levels were 2.5 times higher (P < 0.0001) among dialysis patients (15.0 +/- 7.7 microg/ml) than among healthy subjects (6.3 +/- 2.0 microg/ml), were independent of age, and were higher (P = 0.03) among women (15.2 +/- 7.9 microg/ml) than among men (14.0 +/- 7.4 microg/ml). For both genders, plasma ADPN levels were inversely related to body mass index values, plasma leptin levels, insulin levels, serum triglyceride levels, and homeostatic model assessment index values. Furthermore, plasma ADPN levels were directly related to HDL cholesterol levels and inversely related to von Willebrand factor levels. Plasma ADPN levels were lower (P < 0.05) among patients who experienced new cardiovascular events (13.7 +/- 7.3 microg/ml) than among event-free patients (15.8 +/- 7.8 microg/ml). There was a 3% risk reduction for each 1 microg/ml increase in plasma ADPN levels, and the relative risk of adverse cardiovascular events was 1.56 times (95% confidence interval, 1.12 to 1.99 times) higher among patients in the first ADPN tertile, compared with those in the third tertile. Plasma ADPN levels are an inverse predictor of cardiovascular outcomes among patients with end-stage renal disease. Furthermore, ADPN is related to several metabolic risk factors in a manner consistent with the hypothesis that this protein acts as a protective factor for the cardiovascular system.
Similar articles
-
Adiponectin and cardiovascular outcomes among hemodialysis patients.Kidney Blood Press Res. 2012;35(4):247-53. doi: 10.1159/000334649. Epub 2012 Jan 26. Kidney Blood Press Res. 2012. PMID: 22286012
-
Plasma adiponectin levels for prediction of cardiovascular risk among hemodialysis patients.Ther Apher Dial. 2014 Apr;18(2):185-92. doi: 10.1111/1744-9987.12065. Epub 2013 Jul 3. Ther Apher Dial. 2014. PMID: 24720410
-
Adiponectin in essential hypertension.J Nephrol. 2002 Sep-Oct;15(5):507-11. J Nephrol. 2002. PMID: 12455716
-
Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease.Nephrol Dial Transplant. 2004 Aug;19 Suppl 5:V67-72. doi: 10.1093/ndt/gfh1059. Nephrol Dial Transplant. 2004. PMID: 15284363 Review.
-
Paradoxical role for adiponectin in chronic renal diseases? An example of reverse epidemiology.Expert Opin Ther Targets. 2009 Feb;13(2):163-73. doi: 10.1517/14728220802658481. Expert Opin Ther Targets. 2009. PMID: 19236235 Review.
Cited by
-
Distribution of serum adiponectin isoforms in pediatric patients with steroid-sensitive nephrotic syndrome.Clin Exp Nephrol. 2021 Sep;25(9):1027-1034. doi: 10.1007/s10157-021-02085-w. Epub 2021 Jun 1. Clin Exp Nephrol. 2021. PMID: 34061287 Free PMC article.
-
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria.Endocrine. 2004 Dec;25(3):207-14. doi: 10.1385/ENDO:25:3:207. Endocrine. 2004. PMID: 15758247 Clinical Trial.
-
The good fat hormone: adiponectin and cardiovascular disease.Curr Atheroscler Rep. 2006 Mar;8(2):94-9. doi: 10.1007/s11883-006-0045-5. Curr Atheroscler Rep. 2006. PMID: 16510042 Review.
-
Adiponectin Receptor gene Polymorphisms are Associated with Kidney Function in Elderly Japanese Populations.J Atheroscler Thromb. 2019 Apr 1;26(4):328-339. doi: 10.5551/jat.45609. Epub 2018 Aug 22. J Atheroscler Thromb. 2019. PMID: 30135333 Free PMC article.
-
Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial.Wien Klin Wochenschr. 2008;120(15-16):478-85. doi: 10.1007/s00508-008-0987-4. Wien Klin Wochenschr. 2008. PMID: 18820852 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical